Company news
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news
Oramed Pharmaceuticals Inc. news releases on 6ix. Latest, Jul 15, 2020: Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin
Press releases — page 3
Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin
July 14, 2020
Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin
June 14, 2020
Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June
May 4, 2020
Oramed Patent in Canada Allowed for Oral Delivery of Proteins
April 6, 2020
Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19
March 31, 2020
Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA
March 18, 2020
Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million
February 26, 2020
Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial
February 25, 2020
Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock
February 25, 2020
Oramed to Present at BIO CEO & Investor Conference
February 3, 2020
Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board
January 29, 2020
Oramed Patent in Europe to be Granted for Oral Delivery of Proteins
January 27, 2020
Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board
January 22, 2020
Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board
January 20, 2020
Oramed Appoints Dr. Arie Mayer to Board of Directors
December 4, 2019
Oramed to Present a Scientific Poster at International Diabetes Federation Congress
December 1, 2019
Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology
November 20, 2019
Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event
November 18, 2019
Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th
November 13, 2019
Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes
November 11, 2019
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference
September 17, 2019
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801
September 16, 2019
Oramed to Present at Three Upcoming Conferences
September 2, 2019
Oramed to Present at World Diabetes Congress
July 9, 2019
Oramed Announces Xiaoming Gao Joins Board of Directors
July 1, 2019
Oramed Provides Clinical Update with Meaningful Data Expected by Year-End
June 17, 2019
Oramed to Present at BIO International Convention
June 2, 2019
Oramed to Present at ThinkEquity Conference
April 28, 2019
Oramed to Present at 3rd Annual Clinical Trials Summit
April 10, 2019
Oramed Patent Allowed in the U.S. for Oral Exenatide
April 3, 2019
Oramed to Present at H.C. Wainwright Global Life Sciences Conference
April 2, 2019